Aditya Bagrodia, MD, FACS, presented “Point-Counterpoint: Active Surveillance for Intermediate-Risk Disease – Pro” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 10, 2023, at Humphreys Half Moon Inn, San Diego, California.
How to cite: Bagrodia, Aditya. “Point-Counterpoint: Active Surveillance for Intermediate-Risk Disease – Pro.” March 10, 2023. Accessed Nov 2024. https://grandroundsinurology.com/point-counterpoint-active-surveillance-for-intermediate-risk-disease-pro/
Point-Counterpoint: Active Surveillance for Intermediate-Risk Disease – Pro – Summary
Aditya Bagrodia, MD, FACS, asserts that active surveillance (AS) for intermediate-risk prostate cancer is a viable option, emphasizing the current epidemic of overtreatment. He shares data from The Prostate Cancer Intervention Versus Observation Trial (PIVOT) showing that after a median of 10 years, between-group differences in all-cause and prostate-cancer mortality were not significant among men who either had radical prostatectomy or AS.
Dr. Bagrodia shares data from the ProtecT trial on 10-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer, and he highlights morbidity data from prostate cancer among the subgroups and points out that over the years about 50 percent of patients on AS had treatment intervention. He draws the conclusion that in unselected patients with intermediate-risk (or worse) prostate cancer, early intervention is not associated with better outcomes. Additionally, many patients on AS may ultimately require treatment.
Dr. Bagrodia lists important aspects of selection such as tumor volume, percentage pattern four, adverse histology, genomic risk classifier, magnetic resonance imaging (MRI) findings, patient comorbidities, and patient compliance. He shares data showing that increased age, prostate-specific antigen (PSA) density, percentage pattern four, and core involvement were all reliable risk factors. Dr. Bagrodia addresses pathology and germline characteristics as important considerations for practitioners. He advises using molecular characteristics to augment National Comprehensive Cancer Network (NCCN) risk groups.
Dr. Bagrodia shares guidelines stating that with asymptomatic patients with limited life expectancy, clinicians should recommend AS and, for patients with favorable intermediate-risk prostate cancer, clinicians should discuss AS, radiation therapy, and radical prostatectomy. He concludes that AS is a guideline-directed option for patients with intermediate-risk prostate cancer. He emphasizes a personalized approach that considers patient comorbidities, disease features, and molecular features.
This lecture is part of a Point-Counterpoint debate. Its opposing lecture is “Point-Counterpoint: Active Surveillance for Intermediate-Risk Disease–Con.”
About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
ABOUT THE AUTHOR
Aditya Bagrodia, MD is an Associate Professor and genitourinary oncology disease team leader in the Department of Urology at UC San Diego Health.
Dr. Bagrodia earned his medical degree from the University of Tennessee Health Sciences Center, graduating with highest honors. He was awarded a Doris Duke Clinical Research Fellowship in clinical research at UT Southwestern Medical Center where he completed his residency in urology. Dr. Bagrodia completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center, where he received an American Urological Association Urology Care Foundation Research Scholars Grant.
Dr. Bagrodia’s clinical practice comprises all urologic malignancies including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He has expertise in complex multidisciplinary management and minimally invasive approaches to urologic surgery.
Dr. Bagrodia’s clinical and research focus is on patients with germ cell tumors. His laboratory centers on sequencing efforts to understand tumor evolution and heterogeneity in germ cell tumors as well as to identify novel biomarkers to recognize occult metastatic disease. On the clinical side, Dr. Bagrodia is actively involved with understanding and overcoming unique socio-epidemiological considerations that adversely impact oncologic outcomes in patients with germ cell tumors. He is also the principal investigator for several germ cell tumor-directed clinical trials.
Dr. Bagrodia has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He is funded through competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT), intramural grants, and NIH funding.
Dr. Bagrodia is the principal author or co-author of more than 190 articles, including more than 50 articles devoted to germ cell tumors, in peer-reviewed publications such as the Journal of Clinical Oncology, Nature Genetics, European Urology, and the Journal of Urology. He is also the co-host of Backtable Urology, a podcast devoted to the practical education of urology providers.
